Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Schellhammer

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The Cochrane Database of Systematic Reviews|April 22, 2008
Five-alpha-reductase Inhibitors for prostate cancer preventionT J Wilt, R MacDonald, K Hagerty, et al.
Urology|February 22, 2001
Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancerP Carroll, C Coley, D McLeod, et al.
Urology|February 22, 2001
Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-upP Carroll, C Coley, D McLeod, et al.
Cancer|July 1, 1992
Locoregional diseaseP Schellhammer, F Debruyne, J Altwein, et al.
European Urology|January 1, 1996
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study GroupM S Soloway, P Schellhammer, R Sharifi, et al.
Urology|April 1, 1997
Assessment of endpoints for clinical trials for localized prostate cancerP Schellhammer, A Cockett, L Boccon-Gibod, et al.
Urology|May 1, 1995
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study GroupP Schellhammer, R Sharifi, N Block, et al.
Urology|January 1, 1996
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study GroupP Schellhammer, R Sharifi, N Block, et al.
Urologic Radiology|January 1, 1984
Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosisE A Zerhouni, P Schellhammer, J C Schaefer, et al.
Radiology|October 19, 2000
Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness CriteriaA Pollack, S B Paryani, D Hussey, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Cochrane Database of Systematic Reviews|April 22, 2008
Five-alpha-reductase Inhibitors for prostate cancer preventionT J Wilt, R MacDonald, K Hagerty, et al.
Urology|February 22, 2001
Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancerP Carroll, C Coley, D McLeod, et al.
Urology|February 22, 2001
Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-upP Carroll, C Coley, D McLeod, et al.
Cancer|July 1, 1992
Locoregional diseaseP Schellhammer, F Debruyne, J Altwein, et al.
European Urology|January 1, 1996
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study GroupM S Soloway, P Schellhammer, R Sharifi, et al.
Urology|April 1, 1997
Assessment of endpoints for clinical trials for localized prostate cancerP Schellhammer, A Cockett, L Boccon-Gibod, et al.
Urology|May 1, 1995
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study GroupP Schellhammer, R Sharifi, N Block, et al.
Urology|January 1, 1996
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study GroupP Schellhammer, R Sharifi, N Block, et al.
Urologic Radiology|January 1, 1984
Management of bleeding renal angiomyolipomas by transcatheter embolization following CT diagnosisE A Zerhouni, P Schellhammer, J C Schaefer, et al.
Radiology|October 19, 2000
Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness CriteriaA Pollack, S B Paryani, D Hussey, et al.
Pageof 3